Iparomlimab (QL1604)

Monoclonal antibody

Phase 3underway

Evidence outlook · registrational

Registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-07-15. The sponsor reported topline results of a Phase 2 study on 2023-12-06 (Qilu reports the pivotal Phase 2 result of iparomlimab in dMMR/MSI-H solid tumors (ORR 45.8%)); that is not the registrational readout.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (1)
Other / comorbidity
NCT07686640 · Shandong Cancer Hospital and Institute
2026-08-15 – 2030-07-15 · Local Advanced Rectal Cancer, Radiotherapy, Immunotherapy
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT04864782 · Qilu Pharmaceutical Co., Ltd.
2020-09-23 – 2023-11-01 · Cervical Cancer
What this study did
NCT04435652 · Qilu Pharmaceutical Co., Ltd.
2020-07-01 – 2022-11-30 · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (31)
Other / comorbidity
NCT07649473 · Fujian Medical University
2026-08-15 – 2033-12-31 · Colon Cancer, Synchronous Liver Metastases
What this study did
NCT07379398 · Tianjin Medical University Cancer Institute and Hospital
2026-04-01 – 2031-01-31 · NSCLC
What this study did
NCT07315035 · The First Affiliated Hospital with Nanjing Medical University
2026-01-01 – 2030-12-31 · Gastric Cancer Stage III
What this study did
NCT07673835 · Obstetrics & Gynecology Hospital of Fudan University
2026-06-06 – 2030-12-31 · Ovarian Cancer
What this study did
NCT07940478 · Fujian Cancer Hospital
2027-01-01 – 2030-09-01 · Hepatecellular Carcinoma
What this study did
NCT07160647 · Sir Run Run Shaw Hospital
2025-08-20 – 2030-08-30 · dMMR/MSI-H-type Rectal Adenocarcinoma
What this study did
NCT06878222 · Obstetrics & Gynecology Hospital of Fudan University
2025-03-15 – 2030-03-31 · Cervical Cancers
What this study did
NCT07085234 · The First Affiliated Hospital of Xiamen University
2025-07-30 – 2029-12-31 · Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
What this study did
NCT07454018 · The First Affiliated Hospital of Soochow University
2026-03-01 – 2029-12-31 · Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
What this study did
NCT06864013 · First Affiliated Hospital of Zhejiang University
2025-01-06 – 2029-12-31 · Locally Advanced Rectal Cancer (LARC)
What this study did
NCT07829874 · Fudan University
2026-10-26 – 2029-09-20 · Biliary Tract Cancer (BTC)
What this study did
NCT07062055 · Shandong Cancer Hospital and Institute
2025-07-25 – 2029-07-25 · Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy, Immunotherapy, Hepatic Artery Infusion Chemotherapy
What this study did
NCT07595523 · Peking University Cancer Hospital & Institute
2026-06-01 – 2029-07-01 · Gastric Cancer
What this study did
NCT07514793 · Fudan University
2026-04 – 2029-04 · Mesothelioma
What this study did
NCT07291401 · Zhongnan Hospital
2025-11-01 – 2029-01-01 · Rectal Cancer Patients
What this study did
NCT07150377 · The Second Affiliated Hospital of Shandong First Medical University
2025-08-24 – 2028-08-24 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07801287 · Tianjin Medical University Cancer Institute and Hospital
2026-09-01 – 2028-08-15 · HCC - Hepatocellular Carcinoma
What this study did
NCT06145308 · Peking Union Medical College
2023-08-15 – 2028-07-10 · Salivary Gland Carcinoma, Precision Therapy
What this study did
NCT07876154 · Xijing Hospital
2025-09-25 – 2028-06 · Locally Advanced Cervical Cancer
What this study did
NCT07026422 · Shandong Cancer Hospital and Institute
2025-04-30 – 2028-05-30 · Rectal Malignant Neoplasms
What this study did
NCT07267078 · Peking Union Medical College Hospital
2025-05-25 – 2028-05-25 · Biliary Tract Cancer
What this study did
NCT07232654 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-11-11 – 2028-02-28 · LOCALLY ADVANCED CERVICAL CANCERS
What this study did
NCT07348861 · Zheng Min
2026-02-01 – 2028-01-01 · Cervical Cancer
What this study did
NCT07310069 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2025-05-01 – 2027-12-30 · Gallbladder Cancer Unresectable
What this study did
NCT07038629 · Tianjin Medical University Cancer Institute and Hospital
2025-09-08 – 2027-09-30 · Esophageal Cancer
What this study did
NCT06930118 · Shanghai Changzheng Hospital
2025-04-10 – 2027-09-30 · Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal Cancer
What this study did
NCT07549906 · Sun Yat-sen University
2026-04-20 – 2026-12-31 · Colon Cancer (Stage II &Amp; III), Immunotherapy, Beta Blocker, Neoadjuvant Chemoimmunotherapy
What this study did
NCT07007728 · Peking University Cancer Hospital & Institute
2025-06-01 – 2026-12-31 · Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
What this study did
NCT04326829 · Qilu Pharmaceutical Co., Ltd.
2020-07-08 – 2023-07 · Advanced Malignant Tumor
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT06602063 · Shanghai Gynecologic Oncology Group
2025-07 – 2030-06 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT07945782 · Tianjin Medical University Cancer Institute and Hospital
2026-12-01 – 2030-02-20 · Locally Advanced Pancreatic Cancer, Immunotherapy Combined With Chemotherapy
What this study did
NCT05603039 · Qilu Pharmaceutical Co., Ltd.
2021-07-01 – 2023-12-30 · Advanced Liver Cancer
What this study did
Phase 1 (2)
Other / comorbidity
NCT05801094 · Qilu Pharmaceutical Co., Ltd.
2020-07-20 – 2023-12-15 · Advanced Solid Tumor
What this study did
NCT05649761 · Qilu Pharmaceutical Co., Ltd.
2019-05-29 – 2023-01-23 · Advanced Solid Tumors
What this study did
Phase 4 (1)
Other / comorbidity
Early phase / not applicable (1)
Other / comorbidity
NCT07139587 · Qingxia Li
2025-09 – 2028-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT06789796 · Qilu Pharmaceutical Co., Ltd.
2025-02 – 2030-03 · Small-cell Lung Cancer
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Iparomlimab (QL1604): this drugPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Cemiplimab
Approved(overall)
Monoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
Dostarlimab
Approved(overall)
Monoclonal antibodyPD-1Partial signal
NCT03602859: Progression Free Survival (PFS) (Up to approximately 316 weeks): Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) 19.19 Months (95% CI 16.59 to 20.99) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) 20.63 Months (95% CI 19.22 to 22.77)
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
Nivolumab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09)
NCT03036098: Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results).
Opdivo Qvantig
Approved(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Pembrolizumab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)
Approved(overall)
Monoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only
Penpulimab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
Retifanlimab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
Tislelizumab
Approved(overall)
Monoclonal antibodyPD-1Partial signal
NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed
NCT03412773: Overall survival, tislelizumab vs sorafenib: median 15.9 vs 14.1 months, hazard ratio 0.85 (95.003% CI 0.712 to 1.019); upper bound below the 1.08 non-inferiority margin, so non-inferior; superiority not shown (one-sided p=0.0398 vs boundary 0.0223) (CT.gov posted results).
Toripalimab
Approved(overall)
Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT04085276: PFS in the intent-to-treat population (this trial's stated primary analysis population): median 8.4 vs 6.9 months, HR 0.77, P=0.0445, toripalimab+nab-paclitaxel vs placebo+nab-paclitaxel. Also reported for the PD-L1-positive population: median 8.4 vs 5.6 months, HR 0.653, 95% CI 0.470-0.906, P=0.0102
Abp 234
Phase 3(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
BAT3306
Phase 3(overall)
Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary
Camrelizumab
Phase 3(overall)
Monoclonal antibodyPD-1Partial signal
NCT04613674: Pathological complete response: 56.8% (126/222) camrelizumab+chemotherapy vs 44.7% (98/219) placebo+chemotherapy; rate difference 12.2% (95% CI 3.3%-21.2%), 1-sided P=.004
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
Cetrelimab
Phase 3(overall)
Monoclonal antibodyPD-1Weak signalFeatured results are safety only
CT-P51
Phase 3(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Enlonstobart
Phase 3(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
MB12
Phase 3(overall)
Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary
Serplulimab
Phase 3(overall)
Monoclonal antibodyPD-1Reliable signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Sintilimab
Phase 3(overall)
Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
Budigalimab
Phase 2/3(overall)
Monoclonal antibodyPD-1not yet graded
NCT03000257: Phase 1 dose-escalation confirmed tolerability and linear PK; RP2D established
Sasanlimab
Phase 2/3(overall)
Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only
Balstilimab
Phase 2(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
SHR-3045
Phase 2(overall)
UndisclosedPD-1not yet gradedNo reviewed efficacy summary
IOV-4001
Phase 1/2(overall)
Cell therapyPD-1not yet gradedNo reviewed efficacy summary
OSE-279
Phase 1/2(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary

Upcoming events

(32 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Iparomlimab (QL1604) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 2Rectal Malignant NeoplasmsRecruiting
Est. primary completion 2026-11-30 · NCT07026422 · CT.gov ↗
What to watch
December 2026 (1)
Phase 2Colorectal Neoplasms, Secondary Malignant Neoplasm of LiverNot yet recruiting
Est. primary completion 2026-12-31 · NCT07007728 · CT.gov ↗
What to watch
2027 (8)
January 2027 (1)
Phase 2Rectal Cancer PatientsRecruiting
Est. primary completion 2027-01-01 · NCT07291401 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal CancerRecruiting
Est. primary completion 2027-04-30 · NCT06930118 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Gallbladder Cancer UnresectableEnrolling by invitation
Est. primary completion 2027-05-01 · NCT07310069 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Locally Advanced Cervical CancerRecruiting
Est. primary completion 2027-07 · NCT07876154 · CT.gov ↗
What to watch
August 2027 (2)
Early phase / not applicableGastric Cancer, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08 · NCT07139587 · CT.gov ↗
What to watch
Phase 2dMMR/MSI-H-type Rectal AdenocarcinomaActive not recruiting
Est. primary completion 2027-08-30 · NCT07160647 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2LOCALLY ADVANCED CERVICAL CANCERSRecruiting
Est. primary completion 2027-11-30 · NCT07232654 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction TherapyRecruiting
Est. primary completion 2027-12-31 · NCT07085234 · CT.gov ↗
What to watch
2028 (15)
January 2028 (2)
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07348861 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-01-25 · NCT07267078 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Cervical CancersRecruiting
Est. primary completion 2028-03-31 · NCT06878222 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1/2Locally Advanced Pancreatic Cancer, Immunotherapy Combined With ChemotherapyNot yet recruiting
Est. primary completion 2028-06-30 · NCT07945782 · CT.gov ↗
What to watch
July 2028 (4)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-07-01 · NCT07595523 · CT.gov ↗
What to watch
Phase 4Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-07-01 · NCT07619235 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy, Immunotherapy, Hepatic Artery Infusion ChemotherapyRecruiting
Est. primary completion 2028-07-25 · NCT07062055 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2HCC - Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-08-15 · NCT07801287 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-09-20 · NCT07829874 · CT.gov ↗
What to watch
December 2028 (5)
Phase 2Acral Melanoma, Mucosal MelanomaNot yet recruiting
Est. primary completion 2028-12 · NCT07347444 · CT.gov ↗
What to watch
Phase 2Colon Cancer, Synchronous Liver MetastasesNot yet recruiting
Est. primary completion 2028-12-31 · NCT07649473 · CT.gov ↗
What to watch
Phase 2Cervical Cancer Stage IVA, Cervical Cancer MetastaticNot yet recruiting
Est. primary completion 2028-12-31 · NCT07035808 · CT.gov ↗
What to watch
Phase 2Gastric Cancer Stage IIINot yet recruiting
Est. primary completion 2028-12-31 · NCT07315035 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07673835 · CT.gov ↗
What to watch
2029 (5)
April 2029 (1)
Phase 2MesotheliomaNot yet recruiting
Est. primary completion 2029-04 · NCT07514793 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2NSCLCNot yet recruiting
Est. primary completion 2029-06-30 · NCT07379398 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Local Advanced Rectal Cancer, Radiotherapy, ImmunotherapyRecruiting
Est. primary completion 2029-07-15 · NCT07686640 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Recurrent Ovarian Cancer, Platinum-sensitive Ovarian CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07454018 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer (LARC)Recruiting
Est. primary completion 2029-12-31 · NCT06864013 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
Phase 2Hepatecellular CarcinomaNot yet recruiting
Est. primary completion 2030-03-01 · NCT07940478 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1/2Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CarcinomaNot yet recruiting
Est. primary completion 2030-06 · NCT06602063 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 December 2023Topline resultQilu reports the pivotal Phase 2 result of iparomlimab in dMMR/MSI-H solid tumors (ORR 45.8%)
Qilu Pharmaceutical · Source ↗
September 2023Filing acceptedChina's CDE accepts the new drug application for iparomlimab in dMMR/MSI-H solid tumors
CN, NMPA · Qilu Pharmaceutical · Source ↗